Prevents malaria. ANDA 208818, held by Lupin. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 208818 (Doxycycline Hyclate), held by Lupin, was first approved by FDA on Sep 27, 2017, with 3 approved supplements and 0 published complete response letters.
Doxycycline hyclate tablet is a tetracycline class drugs indicated for: Rickettsial infections Sexually transmitted infections Respiratory tract infections Specific bacterial infections Ophthalmic infections Anthrax, including inhalational anthrax (post-exposure) Alternative treatment for selected infections when penicillin is contraindicated Adjunctive therapy for acute intestinal amebiasis and severe acne Prophylaxis of malaria To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate tablets and other antibacterial drugs, doxycycline hyclate tablets should be used only to treat or prevent infections that are proven or strongly suspected to …
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 27, 2017 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 75MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 150MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Jul 12, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 12, 2023 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 26, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 27, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters